2024 Revenues ($USD) : $8.76B

Bausch Health put up some strong numbers for 2024, hitting $9.63 billion in consolidated revenues, which marked a 10% reported jump (or 8% organically) and landed at the high end of its own guidance. This performance extended its positive run, marking the seventh straight quarter of year-over-year growth for both revenue and adjusted EBITDA.

Adjusted EBITDA also looked good, climbing 10% to $3.31 billion and beating expectations. The company noted this growth wasn’t just isolated; it was pretty consistent across all its business segments, showing the strength of its diverse portfolio. The Bausch + Lomb eye health unit certainly pulled its weight, contributing $4.79 billion to that top line for the year.

Despite the positive revenue and adjusted EBITDA story, the bottom line on a standard GAAP basis was still in the red for the full year, showing a net loss of $46 million. That said, it did manage to post GAAP net income of $93 million in the fourth quarter, maybe hinting at some improvement there.

Looking ahead, CEO Thomas J. Appio sounds confident about carrying this momentum into 2025, pointing to strategic investments and progress on key initiatives. Analysts seem to acknowledge the consistent performance recovery and the operational improvements fueled by that diversification. But the focus now is likely on turning that growth into sustained profitability. Key areas to keep an eye on will be the performance of segments like Bausch + Lomb, progress on those strategic goals, and how the company manages its debt and cash flow.